Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use by Paul W. O’Connor et al.
ORIGINAL COMMUNICATION
Teriflunomide reduces relapse-related neurological sequelae,
hospitalizations and steroid use
Paul W. O’Connor • Fred D. Lublin • Jerry S. Wolinsky • Christian Confavreux •
Giancarlo Comi • Mark S. Freedman • Tomas P. Olsson • Aaron E. Miller •
Catherine Dive-Pouletty • Gae¨lle Be´go-Le-Bagousse • Ludwig Kappos
Received: 22 February 2013 / Revised: 21 May 2013 / Accepted: 25 May 2013 / Published online: 14 July 2013
 Springer-Verlag Berlin Heidelberg 2013
Abstract Multiple sclerosis (MS) relapses impose a
substantial clinical and economic burden. Teriflunomide is
a new oral disease-modifying therapy approved for the
treatment of relapsing MS. We evaluated the effects of
teriflunomide treatment on relapse-related neurological
sequelae and healthcare resource use in a post hoc analysis
of the Phase III TEMSO study. Confirmed relapses asso-
ciated with neurological sequelae [defined by an increase in
Expanded Disability Status Scale/Functional System
(sequelae-EDSS/FS) C30 days post relapse or by the
investigator (sequelae-investigator)] were analyzed in the
modified intention-to-treat population (n = 1086).
Relapses requiring hospitalization or intravenous (IV)
corticosteroids, all hospitalizations, emergency medical
facility visits (EMFV), and hospitalized nights for relapse
were also assessed. Annualized rates were derived using a
Poisson model with treatment, baseline EDSS strata, and
region as covariates. Risks of sequelae and hospitalization
per relapse were calculated as percentages and groups were
compared with a v2 test. Compared with placebo, teri-
flunomide reduced annualized rates of relapses with
sequelae-EDSS/FS [7 mg by 32 % (p = 0.0019); 14 mg
by 36 % (p = 0.0011)] and sequelae-investigator [25 %
(p = 0.071); 53 % (p \ 0.0001)], relapses leading to hos-
pitalization [36 % (p = 0.015); 59 % (p \ 0.0001)], and
relapses requiring IV corticosteroids [29 % (p = 0.001);
34 % (p = 0.0003)]. Teriflunomide-treated patients spent
fewer nights in hospital for relapse (p \ 0.01). Terifluno-
mide 14 mg also decreased annualized rates of all hospi-
talizations (p = 0.01) and EMFV (p = 0.004). The impact
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of teriflunomide on relapse-related neurological sequelae
and relapses requiring healthcare resources may translate
into reduced healthcare costs.
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Introduction
Multiple sclerosis (MS) relapses are variable in nature,
typically last from a week to a month, vary in severity, and
significantly impact patients, their families, and their
caregivers [4, 12, 16]. Severe relapses (e.g., those requiring
hospitalization) are associated with a substantial economic
burden [9, 10, 18]. Although periods of remission usually
follow a relapse (especially during the early phase of MS),
symptoms often do not completely resolve, with residual
neurological deficits persisting in up to 57 % of patients,
which contributes further to disability progression [7].
Variability in recovery also means that patients often
require different levels of care [6, 9, 15].
Teriflunomide is a new once-daily oral disease-modi-
fying therapy recently approved for the treatment of
relapsing forms of MS (RMS) [1]. The Phase III TEMSO
(TEriflunomide Multiple Sclerosis Oral) trial showed that
both doses of teriflunomide (7 and 14 mg) reduced the
annualized relapse rate by over 31 % (p \ 0.001 vs.
placebo); disability progression confirmed for 12 weeks
(14 mg only) and magnetic resonance imaging (MRI)
parameters of disease burden and activity were also
significantly reduced with evidence of a dose effect [11,
17]. Teriflunomide was well tolerated with a well-char-
acterized safety profile, with similar incidences of
adverse events (AEs), serious AEs (SAEs), and AEs
leading to drug discontinuation in the two teriflunomide
groups and the placebo group. The most frequent AEs
with teriflunomide (incidence C10 % and C2 % greater
than placebo) were alanine aminotransferase increases,
alopecia (hair thinning), diarrhea, influenza, nausea, and
paresthesia [1].
This post hoc analysis of TEMSO evaluated the effects




The TEMSO trial (NCT00134563) was a 2-year, multi-
national, multicenter, randomized, double-blind, placebo-
controlled, parallel-group study designed to evaluate the
efficacy and safety of teriflunomide in reducing the fre-
quency of relapses and delaying accumulation of physical
disability in patients with RMS. Detailed methodology of
the TEMSO study has been published previously [11, 17].
Briefly, eligible patients were aged 18–55 years, met
McDonald criteria for MS [8], and exhibited a relapsing
clinical course, with or without progression. For enroll-
ment, patients were required to be ambulatory [Kurtzke’s
Expanded Disability Status Scale (EDSS) [5] score B5.5],
with at least two clinical relapses within the previous
two years, or at least one during the preceding year, but
with no relapses within 60 days of randomization. Patients
were stratified by baseline EDSS score (B3.5 vs.[3.5) and
were randomized 1:1:1 to receive either placebo, teriflun-
omide 7 or 14 mg, once daily for 108 weeks. The primary
study objective was to determine the efficacy of terifluno-
mide in reducing the annualized relapse rate. Secondary
study objectives included determining the efficacy of teri-
flunomide on delaying the progression of the disease over
the duration of the study (key secondary objective), MRI
parameters (principally total lesion volume), and patient-
reported fatigue (by the Fatigue Impact Scale).
Standard protocol approvals, registrations, and patient
consents
The TEMSO trial was performed in accordance with the
International Conference on Harmonisation Guidelines
for Good Clinical Practice and the Declaration of Hel-
sinki. The protocol was approved by central and local
ethics committees and each site’s institutional review
board; patients gave written informed consent prior to
the study.
Study evaluations
This post hoc analysis evaluated the effect of teriflunomide
treatment on outcomes from protocol-defined confirmed
relapses occurring between treatment randomization and
treatment discontinuation in the TEMSO study. Suspected
relapses were defined as the appearance of a new clinical
sign/symptom, or clinical worsening of a previous sign/
symptom that persisted for a minimum of 24 h in the
absence of fever. Patients were required to visit the
investigational site within seven days following onset of a
suspected relapse. Confirmed relapses required either an
increase in EDSS score of C0.5 points (or C1.0 point when
EDSS = 0 at the previous assessment), or a 1-point change
in the Functional System (FS) in at least two systems or a
2-point change in one system (excluding bowel/bladder
and cerebral) from the last EDSS/FS assessment. Suspected
and confirmed relapses could be treated with intravenous
(IV) corticosteroids according to the investigator’s
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judgment; the preferred regimen was methylprednisolone
sodium succinate 1 g once daily for 3–5 days.
The following relapse outcomes were evaluated: relap-
ses with sequelae, relapses associated with increased
healthcare resource use (i.e., hospitalization or requiring IV
corticosteroids), and relapse intensity subjectively rated as
mild, moderate, or severe by the investigator at the initial
relapse assessment.
Relapses with sequelae were defined in two ways:
objectively by confirmed changes in EDSS/FS (sequelae-
EDSS/FS) or subjectively by the investigator (sequelae-
investigator). The objective definition utilized an increase
of EDSS/FS as defined for a confirmed relapse in the
TEMSO primary analysis (see above), but at a different
time point. Thus, any increase of EDSS/FS was derived
using the last assessment before the start of the relapse and
the assessment done at least 30 days post relapse. As
sequelae may persist beyond 30 days, the derivation was
also performed using assessments carried out at least 60,
90, 120, 150, and 180 days post relapse. In cases where two
successive relapses occurred without any EDSS/FS
assessment performed between, the first relapse was
excluded from the analysis. Sequelae subjectively deter-
mined by the investigator were defined as relapses that
resulted in incomplete neurological recovery at the end of a
relapse as reported by the treating neurologist in the relapse
section of the Case Report Form (CRF), where outcomes
were defined as either recovered with sequelae (including
worsened intensity, ongoing, or unknown) or without
sequelae. No further specific recommendations were pro-
vided to investigators to assess relapse recovery and/or the
presence or absence of sequelae.
The impact of teriflunomide treatment on healthcare
resource consumption was also evaluated. These assess-
ments included confirmed relapses for which hospitaliza-
tion was required, confirmed relapses requiring IV
corticosteroids, length of stay in hospital due to a con-
firmed relapse, all hospitalizations, and any emergency
medical facility visits (EMFV; a visit to a medical facility/
hospital for emergency care not resulting in admission).
The ‘all hospitalization’ outcome documented hospital-
izations recorded either from the adverse event form or the
relapse form and was included to evaluate the treatment
effect of teriflunomide on all hospitalizations observed in
the study.
Statistical analyses
Consistent with the primary analysis of TEMSO, all post
hoc analyses described herein were performed on the
modified intention-to-treat population (i.e., all patients
randomized and exposed to study medication for at least
one day; n = 1086) according to the treatment group as
randomized. All analyses on relapse outcomes were con-
ducted on protocol-defined relapses. The number and per-
centage of patients free of relapse were summarized for
each relapse outcome. Adjusted annualized rates were also
calculated for all relapse outcomes, all hospitalizations, and
EMFV using a Poisson regression model with robust error
variance, which accommodates potential over-dispersed
data appropriately. The total number of the outcome of
interest was defined as the response variable; treatment,
EDSS strata at baseline, and region were covariates; and
log-transformed standardized study treatment duration was
defined as an offset variable. Risks of sequelae, hospital-
ization, and requirement for IV corticosteroids per relapse
were calculated as raw percentages observed over the
course of the study; treatment groups were compared with
a v2 test versus placebo. The number of nights spent in
hospital for relapse and EMFV over the study period was
summarized per year. Among all relapses, raw percentages
of relapses rated mild or moderate/severe intensity as per
investigator judgment were presented in each treatment
group and compared versus placebo using a v2 test.
Results
Baseline demographics
Baseline demographics and disease characteristics of the
TEMSO study population have been described previously
[11]. No significant differences were observed across the
three treatment groups.
Effects of teriflunomide treatment on relapse outcomes
Relapses with sequelae: sequelae-EDSS/FS
The annualized rate of relapse with sequelae, defined by
EDSS/FS increase at 30 days post relapse, was lower in
both teriflunomide groups than in the placebo group (pla-
cebo 0.271; teriflunomide 7 mg 0.185; teriflunomide
14 mg 0.173) [Fig. 1a (i)]. Both doses of teriflunomide
reduced the annualized rate of relapse with sequelae-
EDSS/FS compared with placebo: 7 mg by 32 %
(p = 0.0019) and 14 mg by 36 % (p = 0.0011) [Fig. 1a
(i)]. The significant treatment effects of both doses of
teriflunomide observed on relapse-related sequelae at
30 days post relapse were maintained on sequelae assessed
up to 180 days post relapse in the teriflunomide 14 mg
group (Fig. 2). In addition, significantly more patients
remained free from relapses with sequelae-EDSS/FS in
both teriflunomide groups compared with placebo
(Table 1). There were no significant differences between
the two teriflunomide groups either in terms of the
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annualized rate of relapse with sequelae-EDSS/FS or in the
number of patients remaining free from such relapses
[Fig. 1a (i); Table 1]. There were also no significant dif-
ferences between any of the treatment groups in the risk of
sequelae-EDSS/FS per relapse [Fig. 1a (ii)].
Relapses with sequelae: sequelae-investigator
The annualized rate of relapse with sequelae, determined at
the end of the relapse by the investigator, was lower in both
teriflunomide groups than in the placebo group (placebo
0.168; teriflunomide 7 mg 0.126; teriflunomide 14 mg
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Fig. 2 Adjusted annualized rate of relapse with sequelae-EDSS/FS
assessed over time. Relapses with sequelae: incomplete neurological
recovery, defined by an increase of EDSS Expanded Disability Status
Scale or FS Functional System between last assessment before relapse
and at least 30 days post relapse, and assessed every 30 days from 30
to 180 days after relapse
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ITT intention to treat, IV intravenous, TEMSO TEriflunomide Multiple Sclerosis Oral
a Relative change: a positive number indicates more patients free from relapse compared with placebo
b Incomplete neurological recovery, defined by an increase in the Expanded Disability Status Scale (EDSS) or Functional system (FS) 30 days
post relapse
c Incomplete neurological recovery, as assessed by the investigator at the end of relapse
d Missing data regarding intravenous (IV) corticosteroid use was reported in 12.6 % of relapses
Fig. 1 Adjusted annualized rates (i) and risk per relapse (ii) for each
outcome analyzed: a relapses with sequelae-EDSS/FS; b relapses
with sequelae-investigator; c relapses leading to hospitalization;
d relapses requiring IV corticosteroids. Relative change: a positive
sign shows a relative increase and a negative sign shows a relative
decrease. Adjusted annualized rates were derived using a Poisson
model with the total number of the outcome of interest as the response
variable and treatment, Expanded Disability Status Scale (EDSS)
strata at baseline and region as covariates, and log-transformed
standardized study treatment duration as an offset variable. Relapses
with sequelae: incomplete neurological recovery, defined by an
increase of EDSS or Functional System (FS) 30 days post relapse,
assessed every 30 days from 30 to 180 days after relapse or
incomplete neurological recovery as assessed by the investigator at
the end of relapse. Missing data regarding intravenous (IV) cortico-
steroid use were reported in 12.6 % of relapses
b
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associated with a non-significant reduction of 25 %
(p = 0.071 vs. placebo), the 14 mg dose reduced the
annualized rate of relapse with sequelae-investigator by
53 % (p \ 0.0001 vs. placebo) [Fig. 1b (i)]. Significantly
more patients also remained free from relapses with
sequelae-investigator in the 14 mg group but not in the
7 mg group compared with placebo (Table 1). Terifluno-
mide 14 mg had a significantly greater treatment effect
than 7 mg on both the annualized rate of relapse with
sequelae-investigator (p = 0.013) and the proportion of
patients free from such relapses (p = 0.016) [Fig. 1b (i);
Table 1, respectively]. Likewise, the risk of sequelae-
investigator per relapse was reduced by 31 % with teri-
flunomide 14 mg (p = 0.010 vs. placebo) [Fig. 1b (ii)],
with the 14 mg dose having a more pronounced treatment
effect than the 7 mg dose (p = 0.002).
Relapses leading to hospitalization
The annualized rate of relapses leading to hospitalization
was lower in both teriflunomide groups than in the placebo
group (placebo 0.139; 7 mg 0.089; 14 mg 0.057) [Fig. 1c
(i)]. Both doses of teriflunomide reduced the annualized
rate of relapses leading to hospitalization compared with
placebo: 7 mg by 36 % (p = 0.015) and 14 mg by 59 %
(p \ 0.0001) [Fig. 1c (i)]. Significantly more patients in
both teriflunomide groups than in the placebo group
remained free of relapses leading to hospitalization
(Table 1). The treatment effects associated with terifluno-
mide 14 mg were more pronounced than with 7 mg for
both the annualized rate of relapses leading to hospital-
ization (p = 0.035) and the proportion of patients free from
such relapses (p = 0.049) [Fig. 1c (i); Table 1]. Teriflun-
omide 14 mg reduced the risk of hospitalization per relapse
by 43 % (p = 0.0005 vs. placebo) [Fig. 1c (ii)], and also
had a significantly greater treatment effect than the 7 mg
dose (p = 0.006).
Variability exists between countries in hospitalization
for MS relapse. However, rates of hospitalization as a
routine practice for relapse were similar across the three
treatment groups (placebo 78 %; teriflunomide 7 mg 79 %;
teriflunomide 14 mg 83 %) while the effects of
teriflunomide 14 mg treatment were consistent between
individual countries participating in the TEMSO study.
Relapses requiring IV corticosteroids
The annualized rate of relapses requiring IV corticosteroids
was lower in both teriflunomide groups than in the placebo
group (placebo 0.428; 7 mg 0.304; 14 mg 0.284) [Fig. 1d
(i)]. Both doses of teriflunomide reduced the annualized
rate of relapses requiring IV corticosteroids compared with
placebo: 7 mg by 29 % (p = 0.0014) and 14 mg by 34 %
(p = 0.0003) [Fig. 1d (i)]. In addition, both doses of teri-
flunomide led to more patients remaining free of relapses
requiring IV corticosteroids compared with placebo
(Table 1). No significant difference was observed between
the two teriflunomide doses for either outcome [Fig. 1d (i);
Table 1]. IV corticosteroid use during relapse was common
and there were no significant between-group differences
with regard to the risk of requiring IV corticosteroids per
relapse [Fig. 1d (ii)].
Relapse intensity
No significant between-group differences were observed
with regard to intensity of relapse, as determined by the
investigator at the time of the initial relapse assessment
(Table 2).
Effects of teriflunomide treatment on healthcare
resource consumption
Over the course of the TEMSO trial, the mean (standard
deviation) number of nights spent in hospital for relapse
per patient was lower in both teriflunomide groups than in
the placebo group [placebo 2.1 (6.5); teriflunomide 7 mg
1.1 (3.5); teriflunomide 14 mg 0.9 (4.1); p \ 0.01 for both
dose groups vs. placebo]. For 1,000 patients treated for
two years, this would translate into 1,000 and 1,200 hos-
pitalized nights for relapse saved with teriflunomide 7 and
14 mg, respectively.
The annualized rate of all hospitalizations was lower in
both teriflunomide groups than in the placebo group
Table 2 Intensity of relapse as assessed by investigator at the onset of relapse (TEMSO modified-ITT population)
Severity of relapse (investigator
assessed)
Number of relapses (%)
Placebo (n = 335
relapses)
Teriflunomide 7 mg (n = 233
relapses)
Teriflunomide 14 mg (n = 227
relapses)
Mild 117 (34.9) 77 (33.0) 90 (39.6)
Moderate/severe 218 (65.1) 156 (66.9) 137 (60.3)
p value vs. placebo (v2 test) – 0.6425 0.2548
ITT intention to treat, TEMSO TEriflunomide Multiple Sclerosis Oral
J Neurol (2013) 260:2472–2480 2477
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(placebo 0.213; teriflunomide 7 mg 0.170; teriflunomide
14 mg 0.140) (Fig. 3a). Teriflunomide 7 mg was associ-
ated with a non-significant reduction of 21 % (p = 0.13 vs.
placebo) whereas teriflunomide 14 mg reduced the annu-
alized rate of all hospitalizations by 34 % (p = 0.008 vs.
placebo) (Fig. 3a). Differences between the two terifluno-
mide groups were not significant.
Teriflunomide 7 mg was associated with a non-signifi-
cant reduction in the annualized rate of EMFV of 31 %
(p = 0.063 vs. placebo), whereas teriflunomide 14 mg
significantly reduced this by 42 % (p = 0.004 vs. placebo)
(Fig. 3b). Differences between the two teriflunomide
groups were not significant.
Discussion
This post hoc analysis of TEMSO evaluated the impact of
teriflunomide on relapse-related neurological sequelae,
hospitalizations and IV corticosteroid use, and healthcare
resource consumption in patients with RMS. Consistent
and positive benefits of teriflunomide treatment were
observed on a range of relapse outcomes characterized
using several definitions. A dose effect of teriflunomide
was also noted for a number of the relapse outcomes
assessed. In addition, teriflunomide-treated patients had
lower rates of healthcare resource use than placebo-treated
patients; teriflunomide-treated patients spent significantly
fewer nights in hospital for relapse, while those receiving
the 14 mg dose had significantly lower annualized rates of
all hospitalizations and EMFV. Based on these findings,
teriflunomide has the potential to reduce total healthcare
resource use and decrease the substantial clinical and
economic burden associated with MS relapses.
Randomized clinical trials in MS traditionally evaluate
treatment effects in terms of overall impact on relapse
frequency. While the challenges of cross-study compari-
sons are exacerbated by the variable severity and sequelae
of relapses and their tendency to decline in frequency over
time, meta-analyses suggest that the current first-line
injectable therapies [i.e., interferon b-1a/1b (IFNb-1a/1b)
and glatiramer acetate] provide significant but largely
similar benefits on relapse frequency [14]. Given the sub-
stantial health and economic burdens associated with MS
relapses, it is also informative to evaluate the effects of
treatment on outcomes from relapse, particularly in terms
of neurological sequelae and their impact on overall
healthcare resource consumption. However, to the best of
our knowledge, such studies are limited. The pivotal pla-
cebo-controlled trial of IFNb-1b showed a twofold reduc-
tion in the frequency of relapses rated as moderate or
severe compared with placebo, which led to a significant
reduction in the number of hospitalizations over the course
of the study [3]. The EVIDENCE trial showed that patients
treated with high-dose IFNb-1a (Rebif; 44 mcg subcuta-
neously three-times weekly) had a lower rate of IV corti-
costeroid use for relapses than patients treated with low-
dose IFNb-1a (Avonex; 30 mcg intramuscularly once
weekly), although there were no differences in the occur-
rence of relapses rated mild, moderate, or severe [13].
More recently, post hoc analyses of the FREEDOMS and
TRANSFORMS studies showed that treatment with fin-
golimod 0.5 mg was associated with fewer severe relapses,
reduced IV corticosteroid use/hospitalization for relapse,
and a reduction in relapses with incomplete recovery
compared with either placebo or Avonex [2]. This post
hoc analysis of the TEMSO data set extends these
observations.
This analysis has limitations that are worthy of further
discussion. First, any post hoc analysis has inherent limi-
tations; the study was not powered a priori to evaluate the
outcomes analyzed herein and therefore, further prospec-
tive confirmation is required to support our observations.
Second, there is an apparent inconsistency between the
positive effects of teriflunomide treatment on certain
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significant benefit of treatment was observed. However,
relapse intensity was assessed by the investigator based on
a subjective rating only. For relapses with sequelae, both a
subjective assessment based on an investigator rating and a
more objective definition were applied which yielded
congruent effects. Furthermore, hospitalization for relapse
is an objective measure to assess relapse severity/intensity
and one in which there is a clear and positive effect of
teriflunomide treatment. Although differences exist
between countries with regard to the management of
relapse, including indications for steroid treatment and the
decision to hospitalize for relapse, the fact that countries
with varying approaches to relapse management were
represented in TEMSO and were evenly distributed across
the three treatment groups increase confidence in the
validity of this outcome. Finally, while we demonstrate a
benefit of teriflunomide treatment in terms of a reduction in
healthcare resource use (as demonstrated by positive out-
comes on IV corticosteroid use, hospitalizations and
EMFV as captured on study CRFs), other factors can also
contribute to the consumption of healthcare resources by
patients with MS. Further studies are required to determine
the effects of teriflunomide treatment on these other con-
tributors to healthcare resource use.
In summary, this post hoc analysis demonstrates that
teriflunomide therapy was associated with a reduction in
the risk of relapse-related residual neurological deficits, IV
corticosteroid use, hospitalization, and EMFV (14 mg dose
only). Consequently, teriflunomide may reduce healthcare
costs associated with relapses.
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